| Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib G Bocci, A Falcone, A Fioravanti, P Orlandi, A Di Paolo, G Fanelli, ... British journal of cancer 98 (10), 1619-1629, 2008 | 115 | 2008 |
| Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer F Loupakis, C Cremolini, A Fioravanti, P Orlandi, L Salvatore, G Masi, ... British journal of cancer 104 (8), 1262-1269, 2011 | 110 | 2011 |
| Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer A Fontana, L Galli, A Fioravanti, P Orlandi, C Galli, L Landi, S Bursi, ... Clinical Cancer Research 15 (15), 4954-4962, 2009 | 106 | 2009 |
| Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells G Bocci, A Fioravanti, P Orlandi, N Bernardini, P Collecchi, M Del Tacca, ... British journal of cancer 93 (3), 319-330, 2005 | 102 | 2005 |
| A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients G Allegrini, A Falcone, A Fioravanti, MT Barletta, P Orlandi, F Loupakis, ... British journal of cancer 98 (8), 1312-1319, 2008 | 91 | 2008 |
| Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers G Allegrini, T Di Desidero, MT Barletta, A Fioravanti, P Orlandi, B Canu, ... Angiogenesis 15, 275-286, 2012 | 84 | 2012 |
| Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1 G Bocci, A Fioravanti, P Orlandi, T Di Desidero, G Natale, G Fanelli, ... Neoplasia 14 (9), 833-IN11, 2012 | 53 | 2012 |
| Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo SM Ferrari, G Bocci, T Di Desidero, G Elia, I Ruffilli, F Ragusa, P Orlandi, ... Oncology reports 39 (5), 2225-2234, 2018 | 52 | 2018 |
| Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new … S Lazzeri, G Ripandelli, MS Sartini, M Parravano, M Varano, M Nardi, ... Angiogenesis 18, 397-432, 2015 | 52 | 2015 |
| VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide P Orlandi, A Fontana, A Fioravanti, T Di Desidero, L Galli, L Derosa, ... British journal of cancer 109 (4), 957-964, 2013 | 51 | 2013 |
| First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study V Marchetti, M Giorgi, A Fioravanti, R Finotello, S Citi, B Canu, P Orlandi, ... Investigational New Drugs 30, 1725-1730, 2012 | 51 | 2012 |
| Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer A Fioravanti, B Canu, G Alì, P Orlandi, G Allegrini, T Di Desidero, ... European journal of pharmacology 619 (1-3), 8-14, 2009 | 50 | 2009 |
| Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo B Canu, A Fioravanti, P Orlandi, T Di Desidero, G Alì, G Fontanini, ... Neoplasia 13 (3), 217-IN3, 2011 | 49 | 2011 |
| VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration S Lazzeri, M Figus, P Orlandi, A Fioravanti, T Di Desidero, E Agosta, ... Pharmacogenomics 14 (6), 623-630, 2013 | 45 | 2013 |
| Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down … T Di Desidero, A Fioravanti, P Orlandi, B Canu, R Giannini, N Borrelli, ... The Journal of Clinical Endocrinology & Metabolism 98 (9), E1465-E1473, 2013 | 44 | 2013 |
| Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration‐resistant prostate cancer patients L Derosa, L Galli, P Orlandi, A Fioravanti, T Di Desidero, A Fontana, ... Cancer 120 (24), 3923-3931, 2014 | 41 | 2014 |
| Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration E Agosta, S Lazzeri, P Orlandi, M Figus, A Fioravanti, T Di Desidero, ... Pharmacogenomics 13 (9), 1037-1053, 2012 | 39 | 2012 |
| In vitro antiangiogenic activity of selective somatostatin subtype‐1 receptor agonists G Bocci, MD Culler, A Fioravanti, P Orlandi, A Fasciani, R Colucci, ... European journal of clinical investigation 37 (9), 700-708, 2007 | 36 | 2007 |
| EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan F Loupakis, C Cremolini, A Fioravanti, P Orlandi, L Salvatore, G Masi, ... Targeted oncology 9, 205-214, 2014 | 35 | 2014 |
| Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer A Fontana, G Bocci, L Galli, M D'Arcangelo, L Derosa, A Fioravanti, ... Journal of the American Geriatrics Society 58 (5), 986-988, 2010 | 34 | 2010 |
